

## **Notice Regarding Capital Alliance Between EPS Holdings, Inc. and Logos Science Co., Ltd. as Strategic Partners**

EPS Holdings, Inc. (Head Office: Shinjuku-ku, Tokyo; Representative Director: Hao YAN; hereinafter “EPSHD”) hereby announces that it has entered into a capital alliance with Logos Science Co., Ltd. (Head Office: Minato-ku, Tokyo; Representative Director: Hideki TANEMURA; hereinafter “Logos Science”) as a strategic partner for the purpose of jointly promoting the provision of solution services in the area of mental health.



### **1. Purpose of Capital Alliance**

EPSHD has been operating an outsourcing business for pharmaceutical and medical device development with CRO<sup>\*1</sup>, SMO<sup>\*2</sup>, and CSO<sup>\*3</sup> at its core. The company conducted a management buyout (MBO) in 2021, and is expanding its activities into new areas with the aim of becoming a solution company for the entire healthcare industry that transcends conventional boundaries.

Logos Science was founded in 2022 by Ig Nobel laureate Hideki Tanemura with the aim of providing new solution services in the area of mental health. Currently, based on joint research with the Institute of Applied Brain Sciences at Comprehensive Research Organization of Waseda University, Logos Science is working on the development of a mental health self-care application “Dr. App®”<sup>\*4</sup> that supports the resolution of problems and difficulties associated with stress-related disorders.

In the clinical study to verify the feasibility of practical application, “Dr. App®” was evaluated for its usability and safety, and obtained favorable results, including significant improvements in outcome measures.

EPSHD and Logos Science will not only form a capital alliance, but will also work as strategic partners to combine EPSHD's knowledge in the healthcare field cultivated through its pharmaceutical and medical device development business with the psychotherapy program which is the base of Logos Science's “Dr. App®.” Through these efforts, the two companies will contribute solving social issues by developing self-care applications in the mental health field, building

evidence for such applications, and promoting marketing activities to develop new solution services in the mental health field that have never existed before.

## **2. Details**

In recent years, there have been an increase in the number of patients with mental illnesses, with a patient survey conducted by the Ministry of Health, Labour and Welfare in 2017, that showing approximately 4.2 million people affected by mental illnesses. Of these, depression, a stress-related illness, accounted for the largest number at 1.27 million. In particular, suicides among young people, declining labor productivity due to presenteeism in companies, and the spread of ambiguous anxiety in the recent COVID-19 pandemic have become social problems.

The Ministry of Health, Labour and Welfare is emphasizing the importance of early detection and prevention of stress-related illnesses through stress checks and other mental health measures in the workplace and measures to prevent overwork. However, awareness of specific prevention measures and self-care methods is not widespread.

Dr. App®, which is currently being developed by Logos Science in collaboration with the Institute of Applied Brain Sciences at Comprehensive Research Organization of Waseda University, replicates cognitive behavioral therapy and other psychotherapies, including Acceptance and Commitment Therapy (ACT), which are conducted by professionals in clinical psychology settings, in an app program. The feasibility of its practical application was confirmed in a clinical study (feasibility study).

By developing a mental health self-care application that combines such psychotherapy programs based on Logos Science's "Dr. App®" with EPSHD's knowledge in the healthcare domain cultivated through its pharmaceutical and medical device development business to provide companies and individuals with a measure of early detection of mental health problems and a quality self-care method, we expect that we can lead the way to the prevention of mental health problems.

EPSHD and Logos Science will work together to bring a mental health self-care application within 2023 especially for companies and workers with the aim of practical use.

Through synergy between the new initiatives of the EPS Group, which is leaping into a new stage as a solution provider 30 years after its establishment, and the initiatives of Logos Science Corporation, which is taking on the challenge of research and development to provide new solution services in the area of mental health, we aim to create value which leads to social innovation.

## **3. Content of Capital Alliance**

EPSHD will acquire [90,000] shares of common stock issued by Logos Science for the purpose of promoting joint business in the area of mental health.

#### **4. Investment Contract Date**

Investment contract date: March 3, 2023

#### **EPS Holdings, Inc.**

EPSHD is a healthcare solutions provider that has been handling all processes from drug discovery and development to sales, marketing, consulting, and various other solutions since its founding as a pioneer CRO in Japan in 1991. EPSHD broadening its businesses as well by also engaging in initiatives to bring new value to pharmaceutical and medical device companies, hospitals, clinics, and academia through efforts that include expansion in China and the rest of Asia, big data and AI, and regenerative medicine. In 2021, EPSHD launched an innovative medicine business and started services to support the clinical development of seeds originating at academic institutions and domestic and global biotech ventures and to support marketing in and outside Japan.

#### **Logos Science Co., Ltd.**

Founded in 2022, Logos Science is engaged in the business of developing apps/systems for stress-related disorders and mental health care. It aims to achieve wellbeing through the science of language and contributes to the realization of a society free of suffering by helping to solve social issues through its application/system development business for stress-related diseases and mental health care.

\*1: Contract Research Organization (CRO)

\*2: Site Management Organization (SMO)

\*3: Contract Sales Organization (CSO)

\*4: Dr. App® is a registered trademark of Logos Science Co., Ltd.

Contact:

EPS Holdings, Inc.

Corporate Communications Office

E-mail : [pr@eps.co.jp](mailto:pr@eps.co.jp)

Logos Science Co., Ltd.

Public Relations

Shimokawa.

E-mail: [info@logossjp.com](mailto:info@logossjp.com)